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INTRODUCTION
As conventional forms of therapy, including chemotherapy and 
radiation, cause damage to healthy tissue and often fail in the 
long-term due to acquired resistance by advanced tumors, new 
approaches are needed. Oncolytic viruses can be engineered to be 
selectively attenuated in normal cells while retaining the cytotoxic 
capacity of wild-type viruses in cancer cells.1 Virus infection also trig-
gers an immune response which may expose cancer cells to recog-
nition by the immune system.2,3 However, in most cases, effective 
therapy necessitates several virus injections which disproportion-
ately boosts immune responses against the virus rather than the 
tumor.4–7
One strategy successfully adopted by the vaccine field to mitigate 
the negative impact of neutralizing antivector immune responses 
has been to switch the vector to another carrying the same tar-
get antigen but appearing distinct to the immune system. This 
approach, termed heterologous prime-boost vaccination, is show-
ing promise both in preclinical models8–10 and in clinical trials,11,12 
and it is no surprise it is garnering interest also in the oncolytic viro-
therapy realm.13,14 A recent study featuring sequential heterologous 
tumor treatment with an oncolytic adenovirus and the Lister strain 
of vaccinia virus demonstrated in two separate syngeneic hamsters 
tumor models a CD3 lymphocyte-dependent tumor clearance in 
up to 70% of treated animals.15 However, in these models, both 
viruses replicated efficiently, a scenario which is unlikely to occur 
in every cancer patient, and the viruses were given intratumorally, 
which does not reveal potential systemic virus-virus interference. 
Moreover, not all patients mount strong T-cell responses, par-
ticularly when immunosuppressed, and therefore, the efficacy of 
oncolytic virotherapy must rely on virus replication and tumor 
oncolysis rather than virus-induced antitumor immune responses. 
In this regard, oncolytic viruses display a varying infectivity range 
for human cancer cells, dependent on both the abundance of virus 
receptors and on intracellular and/or paracrine factors regulating 
virus replication, notably type I interferon (IFN-I).16,17 Tumor per-
missiveness to oncolytic viruses may be influenced also by prior 
chemo- or radiotherapy, which may activate IFN-I signaling.18
Considering the heterogeneous nature of human tumors and 
possible loss of permissiveness to infection either before or after 
virus injection, we explored the efficacy and safety of heterologous 
adeno-/vaccinia virus therapy under conditions where replication 
of one of the viruses (adenovirus) was basally or progressively lim-
ited. We demonstrate that while both viruses can cotransduce can-
cer cells in vitro, they prefer mutual exclusion and do not enhance 
each other’s replication. This does not, however, seem to limit coin-
fection of primary human tumor tissue ex vivo or human tumor 
xenografts in vivo, where both viruses were able to infect heter-
ologously preinfected distant tumor nests upon intravenous virus 
administration. Importantly, vaccinia virus was able to increase 
therapeutic efficacy in a model of acquired cancer resistance to 
adenovirus, suggesting beneficial virus cooperation via paracrine 
modulation of tumor antiviral defenses. Finally, we confirm in the 
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poorly adenovirus-permissive mouse B16.OVA melanoma model 
that heterologous virus treatment still affords similar efficacy as 
single virus treatment and also results in a significant delay in neu-
tralizing adenovirus antibody induction. Taken together, our results 
highlight that heterologous virotherapy could be effective in situ-
ations where tumors have been rendered virus-resistant to at least 
one of the viruses.
RESULTS
Oncolytic adenovirus and vaccinia virus preferentially occupy 
individual infection niches but do not prevent each other’s replication 
in human cancer cell cultures and primary tumor tissue
Heterologous virus infection in human cells may lead to enhance-
ment or inhibition of replication of either virus, depending both on 
virus-induced paracrine factors and on heterologous interactions 
within the same cell, potentially affecting combination therapy effi-
cacy and safety.19–21 We therefore assessed how oncolytic adenovi-
rus (Ad5/3-Δ24-TK/GFP) and vaccinia virus (vvdd-tdTomato) interact 
in tumor cells in vitro by coinfecting several human cancer cell lines 
permissive for both viruses and analyzed the cells by fluorescence- 
and electron microscopy and viability (MTS) assay.
Even at saturating doses of both viruses (10 PFU per cell for vac-
cinia virus, 100 PFU per cell for adenovirus), double marker gene-
positive cells did not exceed 10% at any time after coinfection 
(Figure 1a, Supplementary Figure 1), implying heterologous virus 
exclusion in individual cells. This was likely reflected as the slight 
(~10%) antagonism in combination cell killing we observed at high 
virus doses (Figure 1b, Supplementary Figure 2. However, cell kill-
ing was synergistic at low virus doses (Supplementary Figure 2) and 
all cells eventually succumbed to progressive virus replication (data 
not shown). Also, we saw mature virus particles even in coinfected 
cells on electron microscopic examination (Figure 1c), and vaccinia 
virus was able to produce plaques on human A549 cell monolayers 
preinfected for up to 12 hours at 100 PFU/cell with Ad5/3-Δ24-TK/
GFP with similar efficiency as on control cell monolayers (Figure 1d). 
Finally, both viruses were able individually as well as in combination 
to establish infection in fresh surgical explant tissue from ovarian- and 
lung carcinoma patients (Figure 1e). While virus marker gene expres-
sion patterns in primary cancer tissue resembled those in cultured 
cells and suggested individual regions of infection, there was neither 
enhancement nor inhibition of replication of either virus when virus 
was quantified from tissue homogenates up to 5 days after infection 
(Figure 1f). Thus, we believe mutual virus exclusion in single cancer 
cells will not pose an obstacle for coinfection of human tumor tissue.
Ongoing intratumoral replication of adeno- or vaccinia virus does 
not interfere with entry/infection of heterologous virus from the 
circulation
While adeno- and vaccinia viruses were able to coinfect tumor tissue 
in culture, it was not clear how the viruses would interact in tumors 
in vivo where virus-triggered innate responses could cause vascu-
lar collapse22 and potentially hinder entry of a superinfecting virus 
in separate tumor nodules or metastatic tumor nests. We there-
fore established bilateral subcutaneous A549 human lung adeno-
carcinoma xenografts in the flanks of nude mice and injected the 
tumor on the right side with either PBS or the first virus, followed 
2 days later by the second virus intravenously and 2 days after that 
extracted and titered both viruses from both tumors (preinjected 
and noninjected) as well as the livers of the animals.
Results show that systemically delivered vaccinia virus was 
able to establish infection in PBS-injected-, adeno-injected– and 
noninjected tumors with equal efficiency, assessed both by plaque 
assay (Figure 2a,b) and qPCR (Supplementary Figure 3a,b). Results 
were similar for adenovirus when analyzed by qPCR, but infectious 
virus was only recovered from tumors preinjected with either vac-
cinia virus or PBS (Figure 2c,d, Supplementary Figure 3c,d). This was 
intriguing, as it implies that prior infection or physical manipulation 
of solid tumor tissue promotes replication of systemically delivered 
oncolytic adenovirus. More importantly, however, these results 
show that the presence of one of the viruses does not preclude 
tumor entry/infection by the other virus.
Adeno-poxvirus combination virotherapy delays IFN-I–associated 
acquired antiviral resistance
Having established that adeno- and vaccinia virus do not preclude 
each other from human cancer tissue in vitro or in vivo, we assessed 
the efficacy of combination therapy in a model of acquired antiviral 
resistance. Disseminated intraperitoneal SKOV3Luc human ovarian 
carcinoma nodules in SCID mice are initially sensitive to adenovirus 
but then become refractory to the virus over repeated intraperi-
toneal virus injections in association with upregulation of several 
IFN-stimulated genes.23 Vaccinia virus, on the other hand, potently 
antagonizes IFN-I signaling through both intracellular and secreted 
molecules and may thereby facilitate replication of IFN-sensitive 
viruses.24,25
We found that addition of vaccinia virus injections into the weekly 
adenovirus regimen caused a significant retardation of tumor 
growth compared to adenovirus alone (Figure 3a). Interestingly, 
the SKOV3Luc tumors seemed to eventually generate resistance 
also to vaccinia virus, which has not been reported before. To 
gain clues about the mechanisms of tumor antiviral resistance, 
we treated SKOV3Luc cells in culture with cytokines with known 
antiviral properties—IFN-β and -γ, tumor necrosis factor (TNF)-α, 
as well as combinations thereof—before virus infection. Results 
show that both adenovirus and vaccinia virus are able to produc-
tively replicate in tumor cells pretreated with IFN-β and -γ, albeit 
with reduced kinetics compared to untreated control cells (Figure 
3b,c). In SKOV3Luc cells, TNF-α did not appear to inhibit either virus. 
However, all infected cells ultimately succumbed (data not shown), 
arguing that additional factors contribute to virus resistance in 
SKOV3Luc cells in vivo.
Adeno-vaccinia combination therapy yields antitumor effects in a 
poorly adenovirus-permissive immunocompetent tumor model
Whereas adeno-vaccinia combination therapy was effective in 
immunocompetent hamsters where both viruses replicate,15 we 
wanted to assess whether heterologous virotherapy would work 
in immunocompetent animals harboring tumors intrinsically semi-
permissive to at least one of the viruses.17,26 We proceeded with sub-
cutaneous B16.OVA mouse melanoma tumors, which are infectable 
by human adenovirus but which do not display significant oncoly-
sis in vitro in our hands (Supplementary Figure 4) and treated them 
with intratumoral virus or PBS injections according to the schedule 
shown in Supplementary Figure 5, which included vaccinia virus at 
1 × 108 PFUs per injection and two consecutive high-dose injections 
of 1 × 1010 viral particles (VPs, roughly equivalent of 2 × 108 PFUs 
in human cells) of adenovirus to evoke an inflammatory response 
even in the absence of virus replication.
Animals receiving an intratumoral “prime” of vaccinia virus 
showed a statistically significant retardation of tumor growth com-
pared to mice in which vaccinia virus was given as a booster, where 
the VV+Ad regimen was more effective than the reciprocal Ad+VV 
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treatment as well as the homologous Ad+Ad regimen (Figure 4a). 
Homologous adenovirus prime-boost resulted in loss of adenovirus 
from all mice at the end of the experiment (Figure 4b), associated 
with greater induction of neutralizing antibodies than in the group 
receiving heterologous Ad+VV prime-boost (Figure 4d). Compared 
to a single injection of adenovirus alone (Ad, d12), a booster injec-
tion of vaccinia virus (Ad+VV) seemed to allow adenovirus to persist 
in the tumors (Figure 4b), although variation within the groups did 
not permit statistical confirmation. Reciprocally, however, boosting 
with adenovirus (VV+Ad) resulted in a statistically significant reduc-
tion of vaccinia virus replication compared to vaccinia virus alone 
(VV, d12) (Figure 4c).
To confirm that vaccinia virus retains its oncolytic capacity in 
B16.OVA tumors whereas adenovirus is not able to lyse these cells, 
we explanted tumor tissue from singly-treated tumors day 6 after 
infection and monitored for cell outgrowth for up to 9 days. Results 
showed cells quickly populated the culture dishes from adenovirus-
treated and PBS-injected tumors, whereas vaccinia virus, confirmed 
Figure 1 Interactions between oncolytic adenovirus and vaccinia virus in vitro and ex vivo. (a) Coinfection of human A549 lung adenocarcinoma cells 
in culture with adenovirus (Ad5/3-Δ24-TK/GFP, 100 PFU/cell, in green) and vaccinia virus (VV-tdTomato, 10 PFU/cell, in red) resulted in up to 10% 
double-infected cells (yellow), as assessed semi-quantitatively from fluorescence micrographs. Other tested ratios of adenovirus to vaccinia virus did 
not improve number of double-positive cells (Supplementary Figure 1). (b) Adeno-vaccinia coinfection of 786-O cancer cells in culture at indicated 
virus concentrations (PFU/cell for both viruses) resulted in roughly similar degree of cell death as with either virus alone, with slight heterologous 
antagonism at high multiplicity of infection, also confirmed by combination index calculation (Supplementary Figure 2). (c) Electron micrographs of 
single or coinfected flow-sorted SKOV3Luc cells (same infection parameters as in a—sorted for GFP+tdTomato+ cells) reveal at 24 hours after infection 
mature adenovirus particles (black arrows) and vaccinia virus particles (white arrows). Virus factories were not seen in coinfected cells, possibly due to 
more rapid dissolution of cellular architechture in these cells compared to singly infected cells. Bars = 500 nm. (d) Vaccinia virus (red) is able to replicate 
and spread in cells preinfected for 12 hours at 10 PFU/cell with human adenovirus (green). Plaques were visualized under fluorescence microscope 72 
hours after vaccinia infection. (e) Ovarian cancer tumor slices (~2 mm3) were prepared manually by scalpel and infected immediately after processing in 
DMEM, 10% FCS with adenovirus (1 × 108 PFU per slice/well) or vaccinia virus (1 × 107 PFU per slice/well) and followed under fluorescence microscope up 
to 7 days. Shown is a representative fluorescence micrograph of a coinfected ovarian cancer tissue (vaccinia red, adenovirus green). (f) Representative 
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by tdTomato expression, destroyed any attaching cells and pre-
vented cell outgrowth (Supplementary Figure 6).
Taken together, our results show that heterologous vaccinia-ade-
novirus treatment is effective even in adenovirus-resistant tumors 
and delays induction of neutralizing adenovirus-antibodies.
Lack of T/B cells or NK cells does not affect heterologous 
virotherapy under single-virus–restricted settings
To understand the role of virus-induced immune responses in the 
vaccinia-biased B16.OVA tumor model during heterologous viro-
therapy, we first characterized the tumor immune infiltrate after 
heterologous virotherapy. We saw a statistically significant increase 
in CD3+CD8+ cells in all virus-treated groups compared to PBS-
injected tumors and a statistically significant increase in NK cells in 
vaccinia primed tumors compared to all other groups (Figure 5a,b). 
To test the functional significance of these immune cell subsets, we 
treated both nude mice, which display a wide range of immune dys-
function including mature T and B cells, and NK-cell–depleted C57 
mice (Supplementary Figure 7) harboring B16.OVA tumors with the 
virus combinations. Vaccinia prime was again more effective than 
adenovirus prime both in nude mice and in NK-depleted animals 
(Figure 5c,d), showing that mature T and B cells or NK cells are dis-
pensable for vaccinia virus oncolytic potency in the B16.OVA mouse 
model, as has been observed also in other tumor models,27,28 and 
highlighting that heterologous vaccinia-adenovirus therapy will be 
effective even under selectively immunocompromised conditions. 
Compared to the recent findings in hamster tumor models where 
both viruses were shown to replicate and where priming with 
adenovirus gave the strongest antitumor efficacy,15 we show bet-
ter efficacy when priming with the more replicating virus in tumors 
resistant to one of the viruses.
DISCUSSION
While the capacity of vaccine vectors to replicate has been proposed 
to be critical for proper CD8 T-cell responses in immunocompetent 
hosts,29 the issue of disparate host cell permissiveness or poten-
tial interference by host innate responses has not been addressed 
with multivirus therapy. Most human cancer cell lines are readily 
infectable and killed by oncolytic viruses in vitro and mathematical 
models are useful to guide curative virus dosing in experimental 
tumors in vivo.30–32 Yet, complete tumor responses in human cancer 
patients are rare and lack of transgene expression in the majority of 
Figure 2 Virus preinfection of tumors in vivo does not preclude superinfection by heterologous virus. Subcutaneous A549 human lung carcinoma 
xenografts were implanted in both flanks of nude mice. When tumors had formed, the graft on the right flank was injected intratumorally with either 
PBS or with 1 × 108 PFU Ad5/3-Δ24 or with 1 × 107 PFU VV-tdTomato. Forty-eight hours later, an i.v. injection was made with either 1 × 108 PFU Ad5/3-
Δ24 or with 1 × 107 PFU VV virus. Forty-eight hours after that, tumors and liver were excised and virus was titered by plaque assay/TCID50. (a,b) Vaccinia 
virus (black triangles) is able upon systemic administration to enter and infect tumors preinfected with adenovirus with equal efficiency as noninfected 
tumors. (c,d) Infectious adenovirus (empty circles) can only be recovered from tumors preinjected by PBS or vaccinia virus (*P < 0.05, Student’s t-test 
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patients following repeated intratumoral or intravesical virus injec-
tions argues that human tumors rapidly mount antiviral defenses to 
halt virus replication.33,34 To address this issue with two promising 
clinical oncolytic virus candidates, adenovirus and vaccinia virus, 
we first we confirmed that the two viruses did not preclude each 
other from human tumor cells in culture/ex vivo or from tumor nests 
in vivo. This information was, on one hand, a prerequisite for test-
ing how a superinfecting virus would affect acquired innate virus 
resistance. On the other hand, coinjection heterologous virotherapy 
is also being developed for clinical applications,35,36 necessitating 
understanding of how viruses interact locally in tumors, where both 
heterologous antagonism and virus enhancement could impact 
safety and efficacy.21
Despite a preference for one virus dominating each cell, possibly 
because of differences in entry and replication kinetics, some dou-
ble-infection did occur with adenovirus and vaccinia virus, even in 
primary human cancer tissue where replication of either virus was 
not affected by coinfection to a significant degree (Figure 1f ). This 
Figure 3 Combination with vaccinia virus is able to control growth of disseminated intraperitoneal virus-resistant ovarian cancer. (a) 5- to 7-week-old 
SCID mice (groups of five mice each) were injected intraperitoneally with 3 × 106 SKOV3Luc cells in 100 μl DMEM. Three days later, mice received an i.p. 
injection of either PBS (vehicle) or 1 × 109 VP adenovirus (Ad5/3-Δ24) (black arrows). Two days after, mice received i.p. either PBS or 1 × 108 PFU vaccinia 
virus (open arrows). The schedule was maintained weekly until study termination. Tumor burden was quantitated by IVIS; shown are means + SD of 
group tumors. This is a model where resistance to adenovirus develops rapidly.23 A similar result emerged for vaccinia virus alone, but when the two 
viruses were combined, a significant (P < 0.05, area under curve) additive reduction in overall tumor burden was observed. (b,c) Adenovirus and vaccinia 
virus titers (PFU/well) 72 hours after infection, respectively, in SKOV3Luc cells pretreated or not with combinations of IFN-I (human recombinant IFN 
β, 5,000 IU/ml final conc.), IFN-II (human recombinant IFN-γ, 500 ng/ml final conc.) or TNF-α (500 ng/ml final conc.) for 4 hours prior to infection with 
adenovirus or vaccinia virus or both (Ad5/3-Δ24-TK/GFP, 10 PFU/cell, VV-tdTomato, 0.1 PFU/cell). Results show a statistically significant reduction (*) of 
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was in contrast to a study combining modified vaccinia virus Ankara 
(MVA) with adenovirus, where coinfection resulted in shutdown of 
adenovirus promoter activity.37 It is likely that innate cell responses 
elicited by MVA, which are known to be greater than those elicited 
by vaccinia virus in many cell types38,39 were responsible for interfer-
ence with adenovirus replication during MVA+Ad coinfection in that 
study. Reciprocally, in our own study in B16.OVA tumors, we noted 
that adenovirus injection into tumors primed with VV resulted in 
reduced VV titers compared to PBS-injected control tumors (Figure 
4c), indicating that in these mouse tumors adenovirus triggered 
responses capable of interfering with VV replication. Such responses 
may involve NK cells, which are antiviral against another oncolytic 
virus, HSV-1,40 and which are induced also in the absence of adeno-
virus replication,41 and antiviral cytokines, such as TNF-α and IFN-I 
and -II to which vaccinia virus in sensitive in mice.27,42
As heterologous virus interference was minimal in human tumor 
tissue ex vivo, we tested and found that both vaccinia virus and ade-
novirus were able to enter and infect tumor tissue in vivo already 
preinfected with the other virus (Figure 2), allowing us to assess 
the impact of heterologous virotherapy on innate paracrine tumor 
defenses. Interestingly, while vaccinia virus entered both injected 
and noninjected tumors with similar efficacy (Figure 2a,b), intra-
venous injection of adenovirus resulted in recovery of infectious 
virus only from PBS- or VV-preinjected tumors (Figure 2c,d). It is 
possible, that physical manipulation of the tumors caused pressure-
induced changes in cell surface receptor expression43 that may have 
facilitated adenovirus entry. Another possibility is that the degree 
of intratumoral blood-clotting increased upon PBS/VV-injection, 
sequestering the intravenously injected adenovirus.44 While inter-
esting, we considered these mechanisms unrelated to heterologous 
virus interactions and therefore beyond the scope of this article.
Subsequently, in the intraperitoneal SCID mouse human ovar-
ian carcinoma SKOV3Luc model, known to acquire resistance to 
adenovirus,23 addition of vaccinia virus resulted in significant tumor 
control over either virus alone (Figure 3a). However, even if IFN-I or 
IFN-γ were able to slow down virus replication in SKOV3Luc cells 
in vitro (Figure 3b,c), these cytokines were unlikely the sole factors 
responsible for the tumor antiviral defense in vivo, as tumors in the 
mice ultimately progressed despite continued injections, whereas 
IFN-pretreated SKOV3Luc cells in culture succumbed. A recent study 
Figure 4 Combination virotherapy reduces tumor burden in immunocompetent mice and delays virus clearance. (a) A summary of two independent 
experiments (n = 10 per group) performed according to the scheme in Supplementary Figure 5 revealed antitumor effects of all treatment regimens 
compared to PBS, and statistically significant difference of VV-primed groups compared to the other groups and a trend toward VV+Ad being the best 
group compared to the next best group, VV+VV (P = 0.0775, AUC). (b) Titration of tumors at study endpoint, 6 days after the last injection, shows that 
vaccinia virus injection into a tumor previously injected with adenovirus (Ad+VV) does not reduce adenovirus titers compared to adenovirus alone 
(Ad d12). This is in stark contrast to the complete elimination of infectious adenovirus in tumors in the homologous Ad+Ad prime-boost group (*P < 
0.05, Student’s t-test on log-transformed virus titers). (c) Vaccinia virus is able to persist for up to 12 days in B16.OVA tumors irrespective of homologous 
prime-boost injection or of the presence of adenovirus but that adenovirus injection into tumors preinfected with vaccinia virus reduces VV titers 
(*) compared to PBS-injection (VV d12). (d) Adenovirus serum neutralizing antibody assay shows that the homologous Ad+Ad regimen significantly 
accelerates neutralizing antibody induction compared to heterologous Ad+VV regimen. Each animal is shown as an individual line. (e) Injection of 
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showed that pretreatment of mice with a replication defective 
human adenovirus vector expressing murine IFN-α generated a sys-
temic protective antiviral response against lethal wild-type vaccinia 
virus challenge,45 demonstrating that innate responses are able 
to control even vaccinia virus, despite that such inhibition is not 
apparent in cultured cancer cells. Therefore, our conclusion is that 
the in vivo microenvironment and/or mouse stroma protects the 
SKOV3Luc cells from the viruses through additional mechanisms 
not apparent in vitro, but that such resistance can still be reduced or 
delayed by reciprocal virus complementation.
From a therapeutic point of view, it is not clear how innate 
responses from virus-exposed normal cells would affect over-
all outcome; while innate responses may slow virus replication/
spread in tumors, it is even possible that overall efficacy would 
be increased, as IFNs have antitumor activity per se and—pos-
sibly even more importantly—are critical in bridging the innate 
and adaptive arms of the immune system.27 However, in the B16.
OVA model in which adenovirus replication is significantly poorer 
than vaccinia virus (Supplementary Figures 5 and 6), but which is 
prone to adenovirus particle-triggered inflammatory responses, 
treatment efficacy was greater in vaccinia- than in adenovirus-
primed mice (Figure 4a), arguing that the more replicative virus 
must compensate for lack of replication of the other. We assessed 
the role of select immune cells that were induced by the combina-
tions (Figure 5a,b) in antitumor efficacy but could not see a clear 
difference in the pattern of tumor control in NK-depleted or nude 
mice compared to normal C57 mice (Figure 5c,d versus Figure 4a); 
again vaccinia virus prime was better than adenovirus prime, and 
may even have produced stronger tumor control than in C57 mice, 
arguing that the analyzed immune cell subsets are antiviral toward 
vaccinia virus, although variation between individual mice did not 
permit firm conclusions. Interestingly, when instead adenovirus 
was used as prime, booster injection of vaccinia virus stabilized 
adenovirus titers in the tumors up until the end of the experiment 
compared to the homologous Ad+Ad group (Figure 4b). Although 
differences to adenovirus alone were not significant, we specu-
late that vaccinia virus may have antagonized innate antiviral 
responses to adenovirus, similarly to VV-mediated facilitation of 
other oncolytic viruses in tumors.26
While vaccinia virus exerted significant tumor control on its own 
in the B16.OVA model, the synergy that is observed upon sequential 
or prime-boost type treatment of tumors with different viruses in 
different types of tumors10,13,14 warrants further scrutiny to optimize 
heterologous prime-boost-type virotherapy for human use in the 
future. Our data shows that acquired tumor resistance or unequal 
permissiveness is not an obstacle for such development and that 
Figure 5 Mature T/B cells or NK cells triggered by heterologous virus injections do not explain antitumor efficacy. Tumors in Figure 4a were minced and 
passed through a 40 μm nylon mesh to create a single cell suspension. After overnight rest at 37 °C, cells were stained and analyzed by flow cytometry. 
(a) Intratumoral adeno- or vaccinia virus injections in the B16.OVA model resulted in a statistically greater influx of cytotoxic T cells (CD3+CD8+) compared 
to PBS. These were not specific for chicken ovalbumin expressed in the B16.OVA cells or endogenous melanocyte antigen TRP2 by pentamer staining 
(data not shown). (b) NK cells (NKp46+) were found more numerous in tumors treated with vaccinia virus as the first injection. Heterologous virotherapy 
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host antiviral responses may be delayed by switching viruses with-
out losing treatment efficacy.
MATERIALS AND METHODS
Cells and viruses
Human renal carcinoma 786-O and lung carcinoma A549 cells were from 
American Type Culture Collection. SKOV3Luc human ovarian carcinoma 
cells have been described.23 Mouse melanoma B16.OVA cells were a kind 
gift of Prof. Richard Vile, Mayo Clinic, MN. Cells were propagated at 37 °C 
and 5% CO
2
 in high glucose Dulbecco’s modified Eagle medium (HyClone) 
supplemented with 10% fetal calf serum (FCS) for human cells or RPMI, 10% 
FCS and 10% G418 for B16.OVA. Ad5/3-Δ24 and Ad5/3-Δ24-TK/GFP have 
been described.46 Vaccinia virus strain Western Reserve deleted described.47 
Vaccinia virus infectious units were determined by standard plaque assay on 
Vero cells where coinfecting adenovirus did not form plaques in the 48-hour 
assay time window. Adenovirus infectious units were determined by stan-
dard 50% tissue culture infective dose (TCID50) assay in A549 cells, where 
coinfecting vaccinia virus was first removed by 0.2 um sterile filtration. 
Adenovirus infectious units are expressed as plaque-forming units (PFU), 
estimated using the formula 1 TCID50 = 0.7 PFU.
Cytotoxicity assays
Cell viability was measured by MTS assay according to manufacturer’s 
instructions (CellTiter 96 AQueous One, Promega, Madison, WI). For testing 
synergistic cell killing, 786-O cells in 96-well plates (50,000 cells per well) 
were infected in sixtuplicate with serial dilutions of vaccinia virus and ade-
novirus, and 72 hours later viability was assessed by MTS and combination 
index calculated using CalcuSyn software (Biosoft) according to the method 
of Chou and Talalay.
Electron microscopy
Cells were gently scraped off and immediately fixed with glutaraldehyde 
(2% final conc) and stored at 4 °C. The next day, cells were dehydrated, 
embedded in LX-112 resin, sectioned and mounted on EM grids and ana-
lyzed under JEOL 1400 Transmission Electron Microscope as described.48
Patients tumor explant tissues
Primary tumor tissue was obtained fresh from the surgical theater under 
Ethics committee permission and informed consent and placed in chilled 
DMEM supplemented with 10% FCS and 2× Penicillin/streptomycin (Life 
Technologies, Gibco, USA). Tumor tissue was promptly cut into small pieces 
manually using scalpel blades and one piece placed per well in a 24-well 
plate with 0.5 ml standard DMEM. Tumor bits in triplicate were infected with 
viruses (Ad5/3-Δ24-TK/GFP, 1 × 108 PFU per slice or vaccinia virus, 1 × 107 PFU 
per slice), and followed under fluorescence microscope over 7 days.
Animal experiments
Nude mouse A549 model. 3 × 106 A549 cells were implanted subcutaneously 
in nude mice. When palpable tumors had formed, grafts on the right flank 
were injected intratumorally with either PBS or with 1 × 108 PFU Ad5/3-Δ24 
or with 1 × 107 PFU VV-tdTomato (n = 3 per group). Forty-eight hours later, 
an i.v. injection was made with either 1 × 108 PFU Ad5/3-Δ24 or with 1 × 107 
PFU VV virus. Forty-eight hours after that, tumors and liver were excised and 
virus was titered by qPCR.
SCID mouse model. 3 × 106 SKOV3Luc cells were injected intraperitoneally 
into 5- to 6-week-old female SCID mice. Three days later, mice were divided 
into groups (n = 5) and received either 100 μl PBS or 1 × 109 VP Ad5/3-Δ24 vi-
rus in 100 μl PBS i.p. Two days later, mice received either 100 μl PBS or 1 × 108 
PFU vaccinia virus in 100 μl PBS. The adeno-vaccinia regimen was repeated 
every week for 4 weeks total so that adenovirus injections were always 7–9 
days apart. Mice were imaged twice a week for the duration of the experi-
ment by IVIS (Xenogen); in brief, each mouse received an i.p. injection of 
3 mg D-luciferin (MBP Bio) in 100 μl PBS and was imaged 8 minutes later for 
10 seconds under isoflurane anesthesia. Experiment was repeated twice.
B16.OVA model. Female mice (nude or C57BL/6) aged 5–6 weeks received 
2.5 × 105 B16.OVA cells subcutaneously in the right flank in 50 μl RPMI. When 
palpable tumors had formed (10 days later), mice were divided into groups 
(n = 5) and received either 50 μl PBS or 1 × 1010 VP Ad5/3-Δ24 virus or 1 × 108 
PFU vaccinia virus in 50 μl PBS i.t. Mice receiving adenovirus received an-
other similar injection the day after. Six days after the first virus injection, 
a separate set of mice (four each) were euthanized for virus titration and 
another set of mice received another intratumoral injection of either ad-
enovirus or vaccinia virus, forming the indicated treatment groups (five to 
six mice each) as depicted in Supplementary Figure 3. Twelve days after the 
first virus injection remaining mice were euthanized and organs and tumor 
extracted for analysis. Experiment was repeated twice.
NK depletion. Anti-asialo GM1 (Wako Chemicals, cat no 986–10001, Neuss, Ger-
many) was diluted 1.4 times with distilled water, then 50 μl per mouse (35.7 
μl undiluted antibody) was given i.p. on days −3, 0, 7, and 15 after tumor im-
plantation. NK-cell depletion was confirmed by FACS (Supplementary Figure 7).
Nude mice. Because of accelerated B16.OVA tumor growth rate in nude 
mice, regimen was altered so that booster was given 3 days after prime and 
animals were euthanized 4 days after that.
Quantitative virus PCR
qPCR for oncolytic adenovirus using E4-specific primers and probe has 
been described.49 Using the same methodology, qPCR for vaccinia virus was 
performed using primers/probe specific for the terminal VGF regions: FWD 
5′-gatgatgcaactctatcatgta-3′, REV 5′-gtataattatcaaaatacaagacgtc-3′, probe 
5′-FAM-agtgcttggtataaggag-3′.
Immunological assays
Tumors from the B16.OVA experiment were minced in RPMI, 10% FCS, sup-
plemented with 2× penicillin/streptomycin (Gibco) through a 40 um nylon 
mesh to create single-cell suspensions. Cells pooled from five mice were 
incubated in 20 cm diameter culture dishes in RPMI at standard culture con-
ditions for 24 hours, following which they were stained with the following 
rat antimouse antibody cocktail (antibodies from BD): NKp46-V450, CD19-PE 
or CD19-FITC, CD3-PerCP-Cy5.5, CD8-PE or CD8-FITC. Additionally, cells were 
stained with pentamers against TCRs specific for MHC-I expressed chicken 
ovalbumin or endogenous melanocyte antigen TRP2 (Proimmune, cat no. 
093 and 185). Labeled cells were washed twice in FACS buffer (2% FBS, PBS) 
and analyzed by flow cytometry (BD FACSAria cytometer, FACSDiva soft-
ware), counting at least 100,000 events per sample.
Statistics
Kaplan–Meier survival data was analyzed by log rank test. Group virus titers 
were log-transformed and compared using two-tailed Student’s t-test. Serial 
measurements (area-under-curve) analysis for IVIS and tumor volume data 
was performed using MedCalc software. Viability data was compared by 
unpaired two-tailed Student’s t-test.
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